GRN

Government of the Republic of Namibia approves entry into pioneering US$10bn Agreement to develop Sub-Saharan Africa's Largest Green Hydrogen Project with Hyphen Hydrogen Energy

Retrieved on: 
Wednesday, May 24, 2023
Hydrogen, Global Gateway, Civil service commission, FIA, GRN, Government, Implementation, Cabinet, Republic, Climate change, GDP, Economic development, Excellency, European Commission, Uranium mining, Renewable energy, EU

WINDHOEK, Namibia, May 24, 2023 /PRNewswire/ -- The Cabinet of the Government of the Republic of Namibia (GRN) has approved entry into an agreement with Hyphen Hydrogen Energy (Hyphen) to govern the development, implementation and operation of sub-Saharan Africa's largest, and its only fully vertically integrated, green hydrogen project.

Key Points: 
  • WINDHOEK, Namibia, May 24, 2023 /PRNewswire/ -- The Cabinet of the Government of the Republic of Namibia (GRN) has approved entry into an agreement with Hyphen Hydrogen Energy (Hyphen) to govern the development, implementation and operation of sub-Saharan Africa's largest, and its only fully vertically integrated, green hydrogen project.
  • At full scale development, anticipated before the end of the decade, the project will produce 2 million tonnes of green ammonia annually.
  • The pioneering Feasibility and Implementation Agreement (FIA) governs the process under which Namibia's first green hydrogen project will be realised, as a first step in the implementation of GRN's broader green hydrogen strategy.
  • On behalf of Hyphen, I would like to thank the Government for its unwavering support and relentless commitment to unlocking Namibia's green hydrogen potential.

Government of the Republic of Namibia approves entry into pioneering US$10bn Agreement to develop Sub-Saharan Africa's Largest Green Hydrogen Project with Hyphen Hydrogen Energy

Retrieved on: 
Wednesday, May 24, 2023
Hydrogen, Global Gateway, Civil service commission, FIA, GRN, Government, Implementation, Cabinet, Republic, Climate change, GDP, Economic development, Excellency, European Commission, Uranium mining, Renewable energy, EU

WINDHOEK, Namibia, May 24, 2023 /PRNewswire/ -- The Cabinet of the Government of the Republic of Namibia (GRN) has approved entry into an agreement with Hyphen Hydrogen Energy (Hyphen) to govern the development, implementation and operation of sub-Saharan Africa's largest, and its only fully vertically integrated, green hydrogen project.

Key Points: 
  • WINDHOEK, Namibia, May 24, 2023 /PRNewswire/ -- The Cabinet of the Government of the Republic of Namibia (GRN) has approved entry into an agreement with Hyphen Hydrogen Energy (Hyphen) to govern the development, implementation and operation of sub-Saharan Africa's largest, and its only fully vertically integrated, green hydrogen project.
  • At full scale development, anticipated before the end of the decade, the project will produce 2 million tonnes of green ammonia annually.
  • The pioneering Feasibility and Implementation Agreement (FIA) governs the process under which Namibia's first green hydrogen project will be realised, as a first step in the implementation of GRN's broader green hydrogen strategy.
  • On behalf of Hyphen, I would like to thank the Government for its unwavering support and relentless commitment to unlocking Namibia's green hydrogen potential.

EQS-News: Greenalia and P2X-Europe join forces to develop an eFuel production project in Galicia

Retrieved on: 
Monday, May 22, 2023
Partnership, Face, R group, GRN, Aviation, H&R, PTL, Wind, Chemical industry, Power, Biomass, CO2, Structural adjustment, Hydrocarbon, Airline, Natural gas, Renewable energy

The initiative envisages a circular process in which, together with green hydrogen, biogenic CO2 would be used to produce the hydrocarbons.

Key Points: 
  • The initiative envisages a circular process in which, together with green hydrogen, biogenic CO2 would be used to produce the hydrocarbons.
  • The CEO of Greenalia, Manuel García, states "this project approaches the process from a circular, global, sustainable and innovative perspective.
  • Through project Breogán, P2X and GRN will strengthen their commitment to the region of Galicia.
  • Already being a leader in renewable energy production, Galicia now has the potential to also become a leader in the production of green molecules such as green hydrogen and synthetic fuels from renewable sources.

EQS-News: H&R GmbH & Co. KGaA: Greenalia and P2X-Europe join forces to develop an eFuel production project in Galicia

Retrieved on: 
Monday, May 22, 2023
Partnership, Frankfurt Stock Exchange, Face, R group, GRN, Aviation, H&R, Wind, Lubricant, Chemical industry, Plasticizer, Biomass, CO2, Hydrocarbon, Airline, Natural gas, Renewable energy, PTL

The initiative envisages a circular process in which, together with green hydrogen, biogenic CO2 would be used to produce the hydrocarbons.

Key Points: 
  • The initiative envisages a circular process in which, together with green hydrogen, biogenic CO2 would be used to produce the hydrocarbons.
  • The products are essentially aimed at aviation and the development of high-value waxes for the chemical industry.
  • For the CEO of Greenalia, Manuel García, "this project approaches the process from a circular, global, sustainable and innovative perspective.
  • Through project Breogán, P2X and GRN will strengthen their commitment to the region of Galicia.

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

Retrieved on: 
Friday, May 19, 2023
Kaufman, UNIPD, Prefrontal cortex, Cerebrospinal fluid, Plasma, Motion, Frasier, Protein, Thalamus, Acquisition, Patient, Atidarsagene autotemcel, Randomized controlled trial, The New England Journal of Medicine, Cell, Disease, IDUA, UOM, Enzyme replacement therapy, Phenotype, DSM-IV codes, Tissue, University, Hip, Gene, Orchard, GRN, Dementia, San Raffaele Hospital, Growth, HSC, Cognition, Natural history, Kyphosis, Biomarker, MPS, Șaeș, Frontotemporal dementia, Webcast, Mortality, Therapy, Central nervous system, Doctor of Philosophy, Speech, HSCT, CNS, EDT, Health, MRI, SGSH, Dysplasia, Society, FTD, Finnish heritage disease, Hippocampus, Medical imaging, Pharmaceutical industry, Vaccine, Medical device, Nursing, Dentistry

BOSTON and LONDON, May 19, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced multiple clinical and preclinical updates from its portfolio of investigational hematopoietic stem cell (HSC) gene therapies in neurometabolic and neurodegenerative disorders. The data are being featured in several oral presentations at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.

Key Points: 
  • The data are being featured in several oral presentations at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.
  • At baseline, most patients presented with severe joint range of motion impairment, severe acetabular (hip) dysplasia and varying degrees of dorso-lumbar kyphosis.
  • Treatment with OTL-203 was generally well tolerated and demonstrated extensive metabolic correction over four years after treatment.
  • Data from in vivo studies indicate effective GRN protein delivery to the CNS of knockout mice transplanted with gene-modified HSCs.

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Thursday, May 11, 2023
PASG, Central nervous system, GM1 gangliosidoses, Cohort, Dose, GRN, Clinical trial, G&A, GM1, CNS, Infant, Patient, Administration, Frontotemporal dementia, Research and development, R, Research, Catalent, FTD, Safety, Pharmaceutical industry

Dose first patient at higher dose (Dose 3) in Imagine-1 clinical trial for GM1 in the second half of 2023.

Key Points: 
  • Dose first patient at higher dose (Dose 3) in Imagine-1 clinical trial for GM1 in the second half of 2023.
  • Present initial safety and biomarker data for Cohort 1 in upliFT-D clinical trial for FTD in the second half of 2023.
  • Research and Development (R&D) Expenses: R&D expenses were $16.8 million for the quarter ended March 31, 2023, as compared to $26.2 million for the same quarter in 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $19.0 million for the quarter ended March 31, 2023, as compared to $15.1 million for the same quarter in 2022.

MetroHealth Joins Guardian Research Network to Expand Research, Patient Care Opportunities

Retrieved on: 
Tuesday, May 2, 2023
GRN, Growth, Partnership, MetroHealth, Research, Health, Patient, Division, RWD, Medicine, Pharmaceutical industry

SPARTANBURG, S.C., May 2, 2023 /PRNewswire/ -- Guardian Research Network®  (GRN) announced today that The MetroHealth System, a multi-hospital safety-net health system serving more than 300,000 Ohio patients, has joined its nationwide healthcare research consortium. This partnership will augment MetroHealth's efforts to become the national leader in translational innovations and discoveries that can improve the health and wealth for all members of the community. Through this strategic collaboration, GRN will continue to leverage real world data (RWD) analytics to strengthen community health initiatives around the country.

Key Points: 
  • SPARTANBURG, S.C., May 2, 2023 /PRNewswire/ -- Guardian Research Network ® (GRN) announced today that The MetroHealth System , a multi-hospital safety-net health system serving more than 300,000 Ohio patients, has joined its nationwide healthcare research consortium.
  • This relationship will open doors to new research opportunities and contribute to the continued growth of MetroHealth's robust translational research programs.
  • Together, GRN and MetroHealth will use these new advances to empower more personalized and clinically impactful care for better outcomes.
  • "We're extremely excited about bringing MetroHealth into our network," said Shirley Trainor-Thomas, vice president, Partner Network of GRN.

GRN Holding Corporation Continues To Execute Business Plan With Acquisition Of California Corporation With Multiple Cannabis Licenses

Retrieved on: 
Thursday, April 20, 2023
OTC Markets Group, Letter, GRN, Consultant, Acquisition, KonoSuba: God's Blessing on This Wonderful World! Legend of Crimson, Corporation, One World, Growth, Drug, Cannabis

With the consummation of this acquisition, the Company filed a supplemental report with OTC Markets to remove the shell status symbol from the OTC Markets webpage.

Key Points: 
  • With the consummation of this acquisition, the Company filed a supplemental report with OTC Markets to remove the shell status symbol from the OTC Markets webpage.
  • The removal of this designation will take the Company one step closer to its previously announced plans for Corporate Restructuring.
  • This will allow them to supply cannabis cultivators with Landrace tissue cultures that are sometimes very hard to obtain.
  • Frank Van Vranken of Mendocino Greens Inc. said, “The opportunity to be part of GRN Holding Corporation opens pathways for growth we did not have before.

Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Monday, March 6, 2023
Ageing, Infant, Webcast, Therapy, FTD, Administration, Biomarker, PASG, GM1, GRN, Research and development, MRI, Central nervous system, Cisterna magna, Patient, Cohort, Urine, Interim, CNS, R, Research, Frontotemporal dementia, Safety, CSF, Pharmaceutical industry, Cryptocurrency

ET

Key Points: 
  • ET
    PHILADELPHIA, March 06, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full-year ended December 31, 2022 and provided recent business highlights.
  • 2023 is an exciting year for Passage as we focus on operational execution and generation of clinical data across our two lead programs.
  • A live audio webcast of the event will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com .
  • The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call.

In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)

Retrieved on: 
Tuesday, February 21, 2023
Physician, GRN, Patient, RDD, Research, Neurodegenerative disease, Immune system, FTD, Disease, FDA, Drug discovery, Frontotemporal dementia, Vaccine, Pharmaceutical industry

and ROSTOCK, Germany and BERLIN, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has extended and expanded the observational EFRONT Study to advance the genetic understanding of frontotemporal dementia (FTD).

Key Points: 
  • and ROSTOCK, Germany and BERLIN, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has extended and expanded the observational EFRONT Study to advance the genetic understanding of frontotemporal dementia (FTD).
  • The announcement comes in the lead-up to Rare Disease Day (RDD) on February 28.
  • “Frontotemporal dementia is a rapidly progressing neurodegenerative disease, with no FDA-approved treatments,” said Kim Stratton, Chief Executive Officer at CENTOGENE.
  • “The EFRONT study helps us understand the genetic factors of the disease with the ultimate goal of advancing therapeutic options for patients living with FTD.”